DEFA14A: Repligen Corrects Proxy Statement Regarding Executive Equity Acceleration

Repligen issues a supplement to its proxy statement clarifying that certain executive equity awards are subject to double-trigger, not single-trigger, acceleration upon a change in control.

Summary

• Repligen has issued a supplement to its definitive proxy statement for the Annual Meeting of Stockholders to be held on May 16, 2024.
• The supplement clarifies that certain disclosures in the original proxy statement, filed on April 1, 2024, were incorrect regarding the acceleration of equity awards for named executive officers (NEOs) upon a sale event.
• Specifically, the initial equity awards granted to Mr. Garland and Mr. Loeillot are subject to double-trigger acceleration, meaning acceleration is triggered only upon termination of the executive by the Company or resignation by the executive for good reason following a change in control.
• The original proxy statement incorrectly reported these awards as subject to single-trigger acceleration.
• The corrected information is reflected in the updated table within the Potential Payments Upon Termination or Change in Control section.
• The table shows the potential payments and benefits for Mr. Hunt and Mr. Bylund assuming a change in control occurred on December 31, 2023, with equity awards assumed, continued, or substituted, and no qualifying termination of employment occurred within 24 months.
• Shareholders of record as of March 18, 2024, do not need to take any action if they have already submitted their proxy unless they wish to change their vote.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. While there was an error in the initial proxy statement, the company is taking corrective action, which is a positive sign. The impact on shareholders is minimal as they are not required to take action unless they wish to change their vote.

Positives

• Repligen is proactively addressing and correcting inaccuracies in its proxy statement, demonstrating transparency and commitment to accurate shareholder communication.

Negatives

• The initial proxy statement contained incorrect information regarding the acceleration of equity awards, which could have misled shareholders.

Risks

• The correction of the proxy statement could raise questions from shareholders regarding the company's internal controls and disclosure processes.

Future Outlook

The document does not contain any specific forward-looking statements beyond the upcoming Annual Meeting.

Industry Context

This announcement is typical of companies ensuring accurate and transparent communication with shareholders regarding executive compensation and corporate governance matters.

Comparison to Industry Standards

• Double-trigger acceleration of equity awards is a common practice among publicly traded companies to align executive interests with shareholder interests during a change in control.
• Companies like Danaher and Thermo Fisher Scientific also employ similar double-trigger mechanisms in their executive compensation packages.
• The specific terms and conditions of these arrangements can vary, but the underlying principle of requiring both a change in control and a qualifying termination is widely adopted.

Stakeholder Impact

• Shareholders are the primary stakeholders impacted by this correction, as it clarifies the terms of executive compensation related to a change in control.
• The correction ensures that shareholders have accurate information when making voting decisions.

Next Steps

• Shareholders of record as of March 18, 2024, should review the corrected information before the Annual Meeting on May 16, 2024.
• Shareholders who wish to change their vote should follow the instructions in the proxy statement.

Key Dates

Keywords

proxy statement, equity awards, change in control, acceleration, executive compensation, Repligen, shareholders